Hou-fu Deng

  • Citations Per Year
Learn More
This study focusses on a promising carrier system for therapeutic and imaging purposes using meso-tetrakis[3,4-bis(carboxymethyleneoxy)phenyl] porphyrin (T3,4CPP). To assess its potential for clinical use, we labelled T3,4CPP with 188Re and analysed some kinetic biodistribution parameters after intravenous injection in mice. T3,4CPP was synthesized and(More)
OBJECTIVE To investigate the biological character of new agent 153Sm-citrate-nano-Hydroxyapatite (nano-HA) in vitro and in vivo, and to explore a new radiopharmaceutical for the target therapy of bone metastasis cancer. METHODS The nano-HA was synthesized by collosol-gelatum method, and evaluated by transmission electron microscopy (TEM) and X-ray(More)
OBJECTIVE To construct and identify the recombinant replication deficient adenovirus vector which codes for human Norepinephrine Transporter (hNET) gene by using the method of homogenous recombination in bacteria. METHODS hNET gene was obtained from the recombinant plasmid pCMV5 via Kpn I + Xba I digestion, and subcloned into E1 deleted expression plasmid(More)
OBJECTIVE To explore the relationship between the standard uptake value (SUV) of 18F-fluorine-2-deoxyglucose (18F-FDG) and the expression of estrogen receptor (ER) in duct carcinoma of breast, as well as their correlation. METHODS From March 2004 to November 2006, PET/CT scans were performed to 41 patients (female, mean age (55.2 +/- 9.55) years) with(More)
Prostate cancer is the most common malignancy in the urinary system of males. The remarkable biological and clinical heterogeneity of prostate cancer poses challenges to the initial diagnosis, differential diagnosis, treatment, and prognosis of the disease. Positron emission tomography/computed tomography (PET/CT) is an ideal imaging tool for noninvasive(More)
OBJECTIVE The aim of this study was to assess the value of Tc-99m-hexakis-2-methoxyisobutylisonitrile (MIBI) scintigraphy diagnosing the malignant and benign bone lesions in comparison with a conventional bone tracer 99Tm-methylene-diphosphonate (MDP). METHODS 99Tc(m)-MDP three-phase bone scintigraphy and 99Tc(m)-MIBI dynamic and quiet states scintigraphy(More)
Strontium-89 (Sr-89) is a pure emitter with maximum beta energy of 1.46 MeV, average beta energy of 0.58 MeV, and a physical half-life of 50.5 days. It is rapidly taken up by bone and preferentially retained at the sites of osseous metastases. Its biological half-life is >50 days at the metastatic sites, but about 14 days only in the normal bone. The dose(More)
  • 1